These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Design and biological evaluation of 3-substituted quinazoline-2,4(1 Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632 [TBL] [Abstract][Full Text] [Related]
12. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
13. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition. El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185 [TBL] [Abstract][Full Text] [Related]
14. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia. Othman EM; Fayed EA; Husseiny EM; Abulkhair HS Bioorg Chem; 2022 Oct; 127():105968. PubMed ID: 35728289 [TBL] [Abstract][Full Text] [Related]
15. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634 [TBL] [Abstract][Full Text] [Related]
16. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Hassan RA; Hamed MIA; Abdou AM; El-Dash Y Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190 [TBL] [Abstract][Full Text] [Related]
17. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies. Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2. Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]